Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin) With GM-CSF and Low-Dose IL-2 as Immune Adjuvants, A Pilot Study.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Aldesleukin (Primary) ; Melanoma vaccine; Sargramostim
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.